Inactief instrument

Andere talen Foamix Pharmaceuticals Ltd. Nasdaq

Aandelen

IL0011334385

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	09/05
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	06/05
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	06/05
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	06/05
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	01/05
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19/03
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29/02
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29/02
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	27/02
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	21/02
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	10/01
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	03/01
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors	03/01
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	13/11
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Foamix Pharmaceuticals Ltd. Nasdaq

Aandelen

IL0011334385

Andere talen

Filters